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Anemia is one of the most common abnormal findings in critically ill patients, and many of these patients will receive a blood
transfusion during their intensive care unit stay. However, the determinants of exactly which patients do receive transfusions
remains to be defined and have been the subject of considerable debate in recent years. Concerns and doubts have emerged
regarding the benefits and safety of blood transfusion, in part due to the lack of evidence of better outcomes resulting from
randomized studies and in part related to the observations that transfusion may increase the risk of infection. As a result of these
concerns and of several studies suggesting better or similar outcomes with a lower transfusion trigger, there has been a general
tendency to decrease the transfusion threshold from the classic 10 g/dL to lower values. In this review, we focus on some of the
key studies providing insight into current transfusion practices and fueling the current debate on the ideal transfusion trigger.
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INTRODUCTION
Transfusions have been in clinical use for over 50 years
and have become an indispensable part of modern medi-
cal practice, especially to allow ever increasing aggressive
therapy in older, sicker, and debilitated patients.1 Approxi-
mately 14 million units of whole blood are collected and
transfused each year, predominately as packed red cell
units.2,3 Other components are manufactured as well, but
the actual use of red cells comes dramatically close to all
the blood that is collected. Yet, in spite of long-standing
utilization and well-entrenched beliefs on the benefits of
erythrocyte transfusion, very few well-conducted studies are
available to support existing clinical practice guidelines.1,4,5
Because of emerging risks associated with transfusion, eco-
nomic consequences, and a few proved benefits, new and
gathering evidence is beginning to be created to answer
controversial questions about transfusion.
Since 1987 when the HIV/AIDS crisis refocused lay
public attention on blood transfusion and infection risks,
specific criteria for transfusion and additional data concern-
ing risks and benefits have become objects of research.1–
3,6,7
 Although advances in transfusion medicine have greatly
decreased the risk of viral transmission during blood trans-
fusion, other issues now drive the debate over transfusion
practice. Such issues are now much more complex, and it
is clear that the concept of blood transfusion as a risk-free
procedure is no longer tenable. The debate over transfu-
sion risks over the last decade has also led to a more criti-
cal examination of transfusion benefits.7 Starting from the
1940s, some questions still remain to be appropriately an-
swered: a) does transfusion improve outcome? b) is anemia
a marker of risk? c) which are the real benefits and risks
of transfusion? d) are there well-conducted studies to guide
transfusion decision making? e) is there a trigger for
hemoglobin in critical patients? f) should cardiac patients
be individualized? g) are there alternative methods to avoid
transfusion?
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The purpose of this review is to determine whether the
existing recommendations for red blood cell transfusions
are adequate answers to these questions, to consider the
available data, and to look for strategies to minimize loss
of blood.
ANEMIA IN THE CRITICALLY ILL
Anemia is very common in critically ill patients; almost
95% of patients admitted to intensive care units (ICU) are
found to have hemoglobin levels below normal by ICU-
day 3.5 As a consequence, critically ill patients receive large
numbers of red blood cell (RBC) transfusions. Studies dem-
onstrate that 50% of all patients admitted to the ICU and
85% who stayed for more than 1 week received at least 1
RBC unit.8
The prospective, multiple-center, observational cohort
CRIT study in the United States, which included 4892 ICU
patients, reported that almost two thirds of such patients
had hemoglobin concentrations of < 12 g/dL.9 The etiology
of anemia is multifactorial (Table 1).
Although primary blood loss from trauma, surgery,
gastrointestinal bleeding, etc, represents a key cause of
anemia in the ICU patient, hemoglobin concentrations de-
crease even in nonbleeding critically ill patients.10 In all
likelihood, the pathogenesis of this decrease in hemoglobin
concentrations in nonbleeding ICU patients is a combina-
tion of losses from phlebotomy and minor procedures, re-
duced red cell production, and possibly increased red cell
destruction.11
Repeated blood sampling can cause significant blood
loss. In the Anemia and Blood Transfusion in Critical Care
Study (ABC), the average daily phlebotomy volume was
41 mL/day.8 An abnormal erythropoietin response to blood
loss, in part related to the effects of inflammatory media-
tors on the production of erythropoietin and of the eryth-
ropoietin receptor12,13 and by induction of apoptosis of
erythroblasts,14 also contributes to the anemia in ICU pa-
tients.15–17 Inflammatory cytokines such as tumor necrosis
factor alpha, interleukin-1, and interleukin-6 have been
shown to directly inhibit erythropoietin production and red
cell formation. Nutritional deficiencies, including iron de-
ficiency, may contribute to decreased production.18 Vasodi-
lation secondary to the inflammatory response may lead
to an increased blood volume, which in turn may contrib-
ute to a decreased hematocrit in spite of a constant red cell
mass. Increased red blood cell (RBC) uptake by the reticu-
loendothelial system due to alterations of the RBC mem-
brane19 could also contribute to the development of anemia
in critically ill patients.
The “Sepsis Occurrence in Acutely Ill Patients study
(SOAP)”,20 which included 3147 patients from European
ICUs, reported that 33% of the patients received a blood
transfusion during their stay.
EFFICACY OF ALLOGENEIC RED BLOOD CELL
TRANSFUSIONS AND TOLERANCE TO ANEMIA
Blood transfusions are given with the aim of improv-
ing oxygen delivery and hence limiting tissue hypoxia and
damage. However, although oxygen delivery is enhanced,
a concomitant increase in tissue oxygenation or oxygen uti-
lization is not a necessary consequence .21–23 In addition,
risks are associated with blood transfusions including trans-
mission of microorganisms; transfusion-related immuno-
modulation, which may increase the risk of infections;
transfusion-related acute lung injury; and human errors
(wrong type and cross-match, incorrect patient identifica-
tion, etc), which can cause hemolytic reactions.
In 1999, Hébert et al24 published the results of a
randomized controlled study that facilitated discussion as
to the real benefits of transfusion. This study compared the
outcomes of critically ill patients managed with a liberal
blood transfusion strategy (hemoglobin concentration kept
at >10 g/dL as was general practice at the time) with a re-
strictive transfusion practice (hemoglobin concentration
maintained at >7 g/dL). Patients in the liberal group re-
ceived a mean of 5.6 units of RBCs, compared with 2.6
units in the restrictive group (P < .01). mortality rates in
the ICU and hospital were lower in the restrictive group,
but the differences were only significant for hospital mor-
Table 1 - Causes of anemia in the intensive care unit patient
Pre-existing chronic anemia
Acquired anemia
Hemodilution
Blood losses
- Surgery, trauma
- Gastrointestinal bleeding
- Other sources of bleeding
- Blood sampling
- Other procedures
Decreased red blood cell production
- Decreased erythropoietin synthesis
- Resistance to erythropoietin
- Iron deficiency
Decreased red blood cell life span
Increased hemolysis
Nutritional deficiencies
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tality (22% vs. 28%, P = .05). In the subgroups of patients
with lower Acute Physiology and Chronic Health Evalua-
tion II scores (< 20) and younger age (< 55 years), mortal-
ity rates were notably lower in the restrictive group than
the liberal group. The authors concluded that “hemoglobin
concentrations should be maintained between 7.0 and 9.0
g per deciliter.”
Although blood transfusions clearly carry risks, avail-
able data clearly show that anemia is associated with worse
outcomes.8,9,25,26 On the other hand, data from animal ex-
periments suggest that acute hemodilution to low
hemoglobin levels is well tolerated; in healthy human vol-
unteers, acute isovolemic reduction of blood hemoglobin
concentration to 5 g/dL yield no evidence of inadequate
systemic oxygenation,27 but side effects such as arrhyth-
mia28 have been observed. However, although healthy in-
dividuals maintain oxygen consumption by corresponding
increases in cardiac index and oxygen extraction ratio dur-
ing isovolemic hemodilution, in critically ill patients, the
relationship between cardiac index and oxygen extraction
may be different.28 Consequently, results from studies in
healthy volunteers are unlikely to be applicable to the ma-
jority of ICU patients. An acceptable hemoglobin concen-
tration is the degree of anemia that is the best balance be-
tween the risks of red cell transfusion and the risks of low
hemoglobin concentration.
Some controversial data suggest a higher risk of death
for patients with anemia. Data obtained from 1958 Jehovah’s
Witness patients undergoing surgery, show a mortality rate
of 1.3% in patients with a preoperative hemoglobin of ³ 12
g/dL and 33.3% in patients with a preoperative hemoglobin
< 6 g/dL. The increase in the risk of death associated with a
low preoperative hemoglobin was more pronounced in pa-
tients with cardiovascular disease.25 In a retrospective study
of 2083 patients who declined RBC transfusion for religious
reasons, the odds of death in patients with a postoperative
hemoglobin level of < 8 g/dL increased 2.5 times for each
gram decrease in hemoglobin level after adjusting for age,
cardiovascular disease, and Acute Physiology and Chronic
Health Evaluation II score.26 In an observational study of
4470 critically ill patients, patients with cardiac disease and
hemoglobin concentrations < 9.5 g/dL a trend toward in-
creased mortality rate (55% vs. 42%, P = .09) was observed,
compared with anemic patients with noncardiovascular dis-
eases.29 Habib et al30 noted that increased hemodilution se-
verity during cardiopulmonary bypass was associated with
worse perioperative vital organ dysfunction/morbidity and
increased resource use, as well as greater short- and inter-
mediate-term mortality.
With the ongoing debate regarding the benefits and risks
of blood transfusions, it is important that each patient is
assessed individually to determine his or her tolerance to
anemia and need for transfusion. However, how can such
patients be assessed? Clinical examination combined with
background data including current diagnosis and comorbid
conditions will help determine the need for transfusion.8
Hemoglobin concentration would be an easy variable and,
indeed, has for years been the guiding factor for the “trans-
fusion trigger;” however, the optimal hemoglobin concen-
tration varies considerably from one patient to the next ac-
cording to multiple factors including age, preexisting
chronic diseases (especially coronary artery disease),
present diagnosis, underlying cause of the anemia, and tol-
erance to anemia.8 Therefore, a single hemoglobin level
below which all patients should be transfused, or a scale
of values for specific groups of patients, is too inflexible a
rule, and maybe subject to errors.
The “critical hemoglobin,” that is, the hemoglobin level
below which oxygen delivery is compromised, would be a
more reliable trigger, but how can this be measured? Cur-
rently, we have only surrogate measures of tissue oxygena-
tion, including mixed venous oxygen saturation, base ex-
cess, and blood lactate levels. Even if we did have an ef-
fective means of detecting tissue hypoxia, should interven-
tions such as blood transfusions be indicated once hypoxia
has already developed?
Commonly used indices of tissue hypoxemia on a whole
body level are oxygen consumption (VO2), plasma lactate
concentration, mixed venous oxygen saturation (SVO2), and
mixed venous oxygen partial pressure (PvO2).31 Regional
indices include gastric tonometry derived indices—pHi and
PCO2 gap. When all such studies are taken into account
there is little evidence that red blood cell transfusion con-
sistently improves clinical indices of tissue hypoxia in
euvolemic critically ill patients. Not even transfusion with
very fresh red blood cells could be shown to improve clini-
cal indices of tissue hypoxia in euvolemic critically ill pa-
tients.31 These data show that although clinicians frequently
transfuse because they are concerned about inadequate oxy-
gen delivery to tissues, this does not usually result in meas-
urable improvements using currently available indices of
tissue hypoxia.32
Thus we return to the hemoglobin concentration as our
guide to transfusion; but at what hemoglobin level should
we transfuse? The study by Hébert et al24 demonstrated that
critically ill patients could be successfully managed with
hemoglobin concentrations between 7 and 9 g/dL, with the
possible exception of patients with acute myocardial
infarcts and unstable angina. Current recommendations for
the management of patients with severe sepsis support a
transfusion trigger of 7 g/dL.33 In addition, studies in
Jehovah’s Witness patients have shown that survival is pos-
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sible at low hemoglobin concentrations; one case study re-
ported survival after a decrease in hemoglobin concentra-
tion to as low as 1.8 g/dL.34 To understand the individual
tolerance to anemia we must discuss oxygen transport and
delivery to tissues.
OXYGEN TRANSPORT
Oxygen delivery (Do2) is defined as the product of car-
diac output (CO) and arterial oxygen content (CaO2) as
shown in the following formula:
DO2 = CO X CaO2
where Do2 is expressed in mL/min, CO in dL/min, and Cao2
in mL/dL.
The arterial oxygen content is expressed by the follow-
ing formula:
CaO2 = (SaO2 x 1.34 x HB) + (0.0031 x PaO2)
where SaO2 is the arterial oxygen saturation (%), 1.34 is
the oxygen-carrying capacity of hemoglobin (mL/g), [Hb]
is the hemoglobin concentration (g/dL), 0.0031 is the solu-
bility of oxygen in plasma at 37°C [mL/(dL·mm Hg)], and
Pao2 is partial O2 pressure in mm Hg.
The ratio of oxygen consumption (VO2)/(Do2) is defined
as oxygen extraction ratio (O2ER). Under normal condi-
tions, O2ER is in the range of 20% to 30% because Do2
(800 to 1200 mL/min) exceeds Vo2 (200–300 mL/min) 3
to 5 fold. Therefore, hemoglobin concentration and thus
Do2 can significantly decrease without affecting Vo2, which
is therefore Do2-independent. However, below a critical
threshold of hemoglobin concentration (HbCRIT) and Do2CRIT,
respectively, Vo2/Do2-dependency is reached. This means
that below this threshold, any further decrease in Do2 or
Hb also results in a decrease in Vo2 and in tissue hypoxia.35
The concept of critical oxygen delivery (Do2CRIT) is impor-
tant to the understanding of cellular hypoxia and shock.
Tissue oxygen delivery is determined by oxygen-carrying
capacity (hemoglobin concentration and the oxy-
hemoglobin dissociation curve) and cardiac output. De-
creases in cardiac output can lead to cardiogenic shock if
the cardiac output falls low enough that Do2CRIT or supply-
independent oxygen delivery to tissues is not met.
This leads to an important question: which physiologi-
cal mechanisms compensate for a decrease in hemoglobin
concentration in anemia in order to maintain Do2 above
Do2CRIT?
Although the extent of compensatory mechanisms to
acute anemia may vary depending on factors such as the
patient’s underlying diseases, the underlying basic princi-
ples remain the same. The basic compensatory mechanisms
to anemia are central, regional, and microcirculatory
changes in blood flow and a shift of the oxyhemoglobin
dissociation curve to the right (a decrease in hemoglobin
affinity for oxygen).36 Acute normovolemic anemia results
in an increase in Cardiac Output27 The decrease in blood
viscosity leads to a facilitated venous return with an in-
creased preload and a decreased afterload.37 In addition,
sympathetic stimulation increases inotropy, contributing
thereby to further increase the output 37 If this is maintained
or allowed to increase in response to dilutional anemia and
if the cardiac preload is maintained, anemia is surprisingly
well tolerated. Compensatory mechanisms for progressive
euvolemic anemia include not only an increase in cardiac
output (increased left ventricular emptying and tachycar-
dia) but also a change in the oxygen extraction ratio from
the erythrocyte itself. Prospective randomized trials42–44 and
an additional meta-analyses38–44 have failed to confirm the
benefit of achieving supranormal values of oxygen deliv-
ery and oxygen use. They have also raised the possibility
that this strategy may result in worse clinical outcomes and
increased mortality. This debate aside, improvement in oxy-
gen delivery is often a clinical goal in the treatment of the
critically ill.
Finally, microcirculatory changes take place leading to
a recruitment of capillaries and homogeneous blood flow
through the capillary bed, which in turn enables increased
oxygen extraction.36
Anemia results in an increase of RBC 2,3-diphospho-
glycerate concentration. This results in a shift of the
oxyhemoglobin dissociation curve to the right, favoring
oxygen release.35,38
The patient’s individual tolerance to anemia is one of
the most important factors regarding decisions on transfu-
sions. Thus, it is mandatory to assess the capacity of each
patient to compensate for an acute decrease in hemoglobin
concentration. The greatest challenge in transfusional prac-
tice today is to determine on an individual basis the toler-
ance to anemia and mechanisms of adaptation.
STUDIES EVALUATING THE OUTCOME OF RED
BLOOD CELL TRANSFUSIONS
Transfusions have been in clinical use for over 50 years
and have become an indispensable part of modern medi-
cal practice, especially to allow for more aggressive therapy
in older, sicker, and debilitated patients. Yet, despite long-
standing utilization and well-entrenched beliefs regarding
the benefits of erythrocyte transfusion, very few well-con-
ducted studies are available to support existing clinical
511
CLINICS 2007;62(4):507-24 Blood tranfusion in critically ill patients: state of the art
Hajjar LA et al.
practice guidelines.45 In 1988, the National Institutes of
Health recommended that the only justification for the
transfusion of red blood cells is the need to augment oxy-
gen transport to the tissues.46 Unfortunately, in 2007, it is
still not possible to determine precisely, in every day clini-
cal practice, when oxygen transport does not meet oxygen
requirements. The lack of well-conducted studies on the
benefits of transfusion and our inability to adequately moni-
tor tissue oxygenation at the bedside have forced clinicians
to rely on “expert opinion” for guidance. We will attempt
to determine if the existing evidence for RBC transfusions
should be re-examined, in light of the few human studies
which are currently available.
One of the first descriptive studies of ICU transfusion
practice was published by Corwin et al in 1995.47 In this
retrospective chart review of 142 ICU patients who had a
length of stay greater than 1 week, 85% had received blood
transfusions. They found that only 35% of the transfusion
events were for acute blood loss, while 29% had no iden-
tifiable trigger. With the exception of the cases in which a
low hematocrit was the trigger, the average pretransfusion
hematocrit was 27%.
Further insight into ICU transfusion practices occurred
in 1998 when Hébert et al published the results of a sur-
vey of Canadian critical care physicians.48 Their data col-
lected from the responses of 193 physicians showed a wide
degree of variability in transfusion practices, with most of
the transfusion thresholds ranging from 8.0 to 10.0 g/dL
hemoglobin. Overall, 35% of physicians selected a trans-
fusion threshold of 9.0 g/dL, and 40% selected a thresh-
old of 10.0 g/dL. Once they decided to transfuse, more than
90% of physicians administered 2 units of RBC.
In all of transfusion medicine, there has been only 1 large
randomized trial to date. This is the Transfusion Require-
ments in Critical Care (TRICC) study by Hébert and col-
leagues.24 The TRICC study enrolled 838 patients and was
the largest trial adequately powered to evaluate the impact
of different transfusion strategies on mortality and morbid-
ity. It has been named the single most important report in
the history of transfusion. It was published in 1998 and was
a cooperative study performed at 25 different Canadian aca-
demic institutions. The patient group studied was a cohort
of medical intensive care patients. Hébert and the Canadian
Clinical Trials Group conducted a randomized controlled
trial of patients in ICUs who were transfused at either 7.0
g/dL or 10.0 g/dL.24 Using the primary endpoint of 30-day
mortality from all causes and several other secondary
endpoints, the authors showed that using the lower transfu-
sion threshold was at least as safe as the higher value. In
several subgroups, such as patients younger than 55 years
and patients with lower severity scores (Acute Physiology
and Chronic Health Evaluation [APACHE] II less than 20),
they found a statistically significant mortality benefit in the
lower transfusion trigger group. Other mortality time points
such as in-hospital mortality and 60-day mortality also
showed a statistically significant benefit to the lower thresh-
old. In addition to these clinical outcomes data, the blood
use was dramatically different in the two groups. The low
transfusion threshold group received about half as many units
of blood (average of 2.6 units versus 5.6 units per patient).
The TRICC study24 documented an overall nonsignificant
trend toward decreased 30-day mortality (18.7% versus
23.3%, P =.11) and significant decreases in mortality among
patients who were less acutely ill (8.7% versus 16.1%, P
=.03) in the group treated using a hemoglobin trigger of 7
g/dL compared with a more liberally transfused group that
received 54% more red cell transfusions. The investigators
also noted that the 30-day mortality rates were significantly
lower with the restrictive strategy among patient who were
less acutely ill (APACHE II scores < 20) and among patients
who were less than 55 years of age.
The findings of the TRICC study found no advantage
to transfusion (Table 2).24 Overall mortality did show just
how ill the group studied had been. The in-house, 30-day
mortality rate did show that patients who had transfusions
at the lower trigger had a statistically lower mortality rate.
The overall myocardial infarction (MI) rate was low, and
the rate was statistically lower in those patients who were
allowed to become profoundly anemic and not have a trans-
fusion. The occurrence of ARDS and pulmonary edema
were also statistically significant and strikingly lower in the
group that received less blood. Of interest, there was no
overall difference in infection rate in the two groups.
Two large multicenter studies have been performed in
the years since the publication of the randomized control-
led trial of Hébert et al that have furthered understanding
of current transfusion practice. The first study was pub-
Table 2 - Results from the TRICC study by Hébert and
colleagues24
Category Restrictive Liberal P value
All patients 18.7 23.3 .10
APACHE II 8.7 16.1 .03
Age < 55 yr 5.7 13.0 .02
Cardiac diagnosis 20.5 22.9 .69
Death in the hospital 22.2 28.1 .05
MI 0.7 2.9 .02
Pulmonary edema 5.3 10.7 < .01
Angina 1.2 2.1 .28
ARDS 7.7 11.4 .06
Infectious 10.0 11.4 .38
Nowhere in these data did patients who had more transfusions do better.
There were large differences in the rate of MI and in pulmonary dysfunctions.
MI = myocardial infarction ARDS = acute respiratory distress syndrome
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lished in 2002 by Vincent et al and titled the ABC study
(Anemia and Blood Transfusion in Critically Ill Patients).8
The stated objectives of this study were to define the inci-
dence of anemia in critically ill patients, describe transfu-
sion practices, and explore possible risks and benefits as-
sociated with transfusion. Data were collected at 146 ICUs
in 15 countries throughout Europe and encompassed 3534
patients. Most of the ICUs (71%) had mixed medical and
surgical patients. First, the sub-study on phlebotomy
showed that blood withdrawal was considerable, averaging
41 mL per day. The rest of the data gives a very good pic-
ture of the average transfusion requirements and practices
in these ICUs. Overall, the transfusion rate for the whole
28-day period (including post-ICU time) was 41% for 3534
patients included. The average hemoglobin level was 11.3
at admission, and the average pretransfusion hemoglobin
was 8.4 g/dL. There was no difference in the average
pretransfusion hemoglobin for patients who were thought
to be actively bleeding (8.4 g/dL) and those who were not
(8.5 g/dL). This is surprising, in that physicians are gener-
ally more likely to transfuse a patient at a higher
hemoglobin level if they know of active bleeding. One fac-
tor that may explain this was that patients transfused for
the indication of coronary artery disease alone had a higher
than average transfusion threshold of 8.7 g/dL.
The data showed a positive correlation between receiv-
ing any blood transfusions and 28-day mortality. The mor-
tality risk increased with the number of units transfused.
The authors then divided the patients by organ dysfunction
scores and showed an increase in mortality in the trans-
fused versus nontransfused patients in all but the most se-
verely ill patients. Finally, a logistic regression model was
used to generate propensity scores for two groups of
matched patients in an effort to adjust for characteristics
other than transfusion. The data, which compared 516 trans-
fused versus 516 nontransfused patients matched for pa-
tient characteristics, showed a significantly higher mortal-
ity in transfused patients (22.7% versus 17.1%; P = 0.02)8.
A multicenter study called the CRIT Study that sought
to quantify transfusional practices of ICUs in the United
States and describe associated clinical outcomes and com-
plications has been published.9 Patients who were admit-
ted to any medical, surgical, or mixed ICU were enrolled
and followed for 30 days or until death or discharge from
the hospital. The study took place at 284 ICUs in 213 hos-
pitals. The ICUs were 31% medical, 29% surgical, and 40%
mixed. Residents were present in 76% of the ICUs, and
71% were open ICUs. The study included 4892 patients
with an average age of 60 years. Overall, ICU and in-hos-
pital mortality rates were 13% and 18%, respectively. Simi-
larly to what was seen in previous studies, the average
hemoglobin declined steadily over time. Overall, 44.1% of
patients were transfused while in the ICU, and 48.2% were
transfused during the total 30-day observation period.9 The
average pretransfusion hemoglobin was 8.6 g/dL. Subgroup
analysis showed a higher threshold for surgical (8.8 g/dL)
than for medical (8.2 g/dL) patients. All patients had se-
verity scores calculated (APACHE II and sequential organ
failure assessment [SOFA]), and there was a positive cor-
relation between severity of illness and the number of units
transfused.
As in previous studies, the authors looked for an asso-
ciation between number of units transfused and clinical
outcomes. Multivariate analysis showed that the number of
RBC units transfused was associated with increased ICU
and hospital length of stay compared with nontransfused
patients. Furthermore, RBC transfusion also was independ-
ently associated with higher mortality rates. As in the ABC
trial, investigators used adjusted case matching analysis to
look for any additional mortality risk conveyed by the trans-
fusion of RBCs independently. Investigators matched 1059
transfused patients to 1059 nontransfused patients and ad-
justed for the propensity for receiving a blood transfusion.
Blood transfusion remained significantly associated with
an increased risk for death (adjusted mortality ratio, 1.65;
95% CI, 1.35–2.03; log-rank P < .001).
Unfortunately as evidenced by a recent systematic re-
view, there is a paucity of clinical trials comparing restric-
tive to liberal transfusion studies to examine the efficacy
of RBC transfusion. Carson et al49 were able to identify
only 10 randomized clinical trials of adequate methodo-
logical quality in which different RBC transfusion triggers
were evaluated. Included were a total of 1780 surgery,
trauma, and ICU patients enrolled in trials conducted over
the past 40 years. The trigger evaluated in these trials var-
ied between 7 and 10 g/dL. Data on mortality or hospital
length of stay was only available in 6 of these trials. Con-
servative transfusion triggers were not associated with an
increase in mortality; on average, mortality was one-fifth
lower (RR 0.80; 95% CI 0.63-1.02) with conservative com-
pared with liberal transfusion triggers. Likewise, cardiac
morbidity and length of hospital stay did not appear to be
adversely affected by the lower use of RBC transfusions.
There was insufficient data on potentially relevant clinical
outcomes such as stroke, thromboembolism, multiorgan
failure, delirium, infection or delayed wound healing to
perform any pooled analysis. Carson and colleagues49 stated
there were insufficient data to address the full range of risks
and benefits associated with different transfusion thresh-
olds, particularly in patients with coexisting disease. They
also noted that their meta-analysis was dominated by a sin-
gle trial: the TRICC trial,8 which enrolled 838 patients and
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was the only individual trial identified that was adequately
powered to evaluate the impact of different transfusion
strategies on mortality and morbidity.
Recently, a study published by Rivers et al50 documented
that the use of early goal-directed care based on
hemodynamic variables and a mixed central venous satu-
ration decreased mortality from 46.5% in the control group
to 30.5% in the goal-directed therapy group (P = .009). The
goal-directed therapy group received more RBC transfu-
sions in the first 6 hours of care and presented higher sur-
vival rates.
The recent SOAP study enrolled 3,147 patients of whom
33% received an RBC transfusion. Patients receiving trans-
fusions were older and generally sicker.20 Therefore, it is
not surprising that mortality rates were higher in transfused
patients. However, after propensity score matching, mor-
tality rates were the same in transfused and in nontransfused
patients, with a tendency towards lower survival in
nontransfused patients. Thus the SOAP study contrasts with
the CRIT and ABC studies; this could be due to implemen-
tation of deleukocytation in Europe.20
Current evidence from studies of the influence of allo-
geneic blood transfusion on efficacy and clinical outcome
is seriously hampered by the absence of a significant
number of adequately powered randomized clinical trials.
However, one point should be considered. Most studies sug-
gest that hemoglobin levels of 7-9 g/dL are well tolerated
by most critically ill patients and that a transfusion thresh-
old of 7 g/dL is appropriate.
TRANSFUSION IN CARDIAC SURGERY
Blood conservation strategies in the cardiac surgery
population are of interest because of the volume of blood
product support provided to these patients and the complex-
ity of the bleeding management issues confronting the pa-
tient care team.51–53 The etiology of excessive bleeding af-
ter cardiac surgery is multifactorial and related to surgical
complexity, the use of anticoagulants/heparin during sur-
gery, the coexistence of multiple hemostatic aberrations
produced during cardiopulmonary bypass, damage to blood
vessel walls during the operation, and the quality of the
surrounding tissue following the procedure. Acquired de-
fects in hemostasis may include coagulopathy from hypo-
thermia, hemodilution, or abnormal fibrinolysis.51 Abnor-
mal platelet contribution to hemostasis also occurs, whether
from prior antiplatelet agents, platelet activation from the
bypass circuit, platelet consumption, or platelet loss.52 De-
spite complete heparin reversal and the use of
antifibrinolytic agents, excessive bleeding still occurs. Ab-
normal or excessive bleeding after cardiac surgery occurs
in 3% to 11% of patients;53,54 it requires surgical re-explo-
ration in approximately 5% of patients,54 in whom inad-
equate surgical hemostasis is identified in up to 50% to
60% of them;55 and increases the risk of mortality 3 to 4
times.56 Excessive bleeding has been associated with CPB
duration exceeding 2.5 hours, repeat or combined cardiac
procedures, renal dysfunction, older age, smaller body sur-
face area, and the use of anticoagulants or antiplatelet
agents.51
Extensive transfusion of allogeneic blood products has
been associated with many adverse events, including bac-
terial infection, viral transmission, transfusion-related acute
lung injury, volume overload, and increased mortality.53,57,58
In spite of some published algorithms and guidelines, large
variability in transfusional practices still persists.59.60
In summary, it is clear that excessive bleeding from
multifactorial causes that occurs after cardiac surgery cre-
ates significant medical and financial burdens. Several stud-
ies suggest that adhering to transfusion algorithms, espe-
cially in conjunction with concomitant hemostasis moni-
toring, may (1) decrease the number of transfusions admin-
istered, (2) decrease the volume of blood lost, and (3) de-
crease the rate of re-exploration for bleeding.51 It is also
evident from these series, however, that optimal hemostasis
monitoring and applicability/predictive value to in vivo
hemostasis can be further refined and awaits additional
clinical investigation.
TRANSFUSION IN HEART DISEASE
Considering the risks and the lack of clear evidence re-
garding the benefits of allogeneic blood,61 the American
Society of Anesthesiologists established the Task Force on
Blood Component Therapy to develop evidence-based in-
dications for the transfusion of red blood cells.62 They con-
cluded that “red blood cell transfusions should not be dic-
tated by a single hemoglobin ‘trigger’ but instead should
be based on the patient’s risk of developing complications
due to inadequate oxygenation.” In addition, they noted that
a blood transfusion generally would be indicated, but would
not be mandatory,62,63 at hemoglobin levels less than 6.0 g/
dL, but very rarely would a blood transfusion be indicated
at hemoglobin levels greater than 10.0 g/dL. The evidence
available at present does not support higher transfusion
thresholds (9-10 g/dL) in patients with cardiovascular dis-
eases.1 However, this group of patients still presents the
highest rates of transfusion. Why continue to recommend
high hemoglobin concentration thresholds in patients with
cardiovascular disease?
Patients with coexisting cardiac diseases may have a
particular risk of developing inadequate oxygenation at low
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hemoglobin levels, either in the form of myocardial
ischemia (in patients with coronary artery disease) or in
the form of an inadequate cardiac output (in patients with
limited cardiac contractile functions).
Regarding the patient’s tolerance to anemia, patients
with cardiovascular disease could be at particular risk. In
coronary artery disease, an adequate increase in the coro-
nary blood flow in response to a decrease in hemoglobin
concentration is not possible, and myocardial ischemia may
develop. In a retrospective cohort study in 1958, patients
who declined blood transfusions for religious reasons cor-
roborated this hypothesis.25 It was found that below a
preoperative hemoglobin level of 10-11 g/dL, mortality in-
creased in patients with and without cardiovascular disease,
but more so in the cardiovascular disease group. Similarly,
in a subgroup analysis of an observational study evaluat-
ing the effect of anemia and blood transfusion strategies
on mortality, Hebert et al found an association between
anemia and risk of death in critically ill patients with car-
diac disease.29 Increasing their hemoglobin values resulted
in improved survival in this subgroup of patients. In pa-
tients with cardiovascular disease, improved outcome with
a liberal transfusion trigger is supported by retrospective
studies. Recently, the retrospective study by Wu et al64 at-
tempted to determine the benefits of red blood cell trans-
fusions in 78,974 elderly patients with acute myocardial
infarction and various degrees of anemia. The study suf-
fered from several limitations including its retrospective
nature; the lack of a temporal relationship between
hematocrit, transfusions, and mortality; and the borderline
statistical significance of the results. In fact, mortality was
increased when the initial hematocrit was below 24% in
nontransfused patients or above 36.1% in transfused pa-
tients. The authors conclude that their data suggest that eld-
erly patients with an acute myocardial infarction will ben-
efit from transfusions whenever the hematocrit on admis-
sion is 30% or lower. The accompanying editorial con-
cluded1: “on the basis of the evidence presented by Wu et
al, we recommend that hematocrit levels should be main-
tained above 33% in patients with acute myocardial inf-
arction.” We find this conclusion incorrect, especially based
in fact that the hematocrit trigger of 33% was not truly sup-
ported by Wu’s data.64
When we look to the evidence coming from randomized
controlled trials, there are a few available data to clarify
the topic. Published studies show no relation between
higher levels of hemoglobin in cardiac patients and lower
mortality. A subgroup analysis of the TRICC trial showed
no differences in mortality rate between the restrictive and
the liberal transfusion strategies in patients with CVD.24
Although the authors claim to be aware of the possible limi-
tations of this subgroup analysis, they suggested that a
transfusion trigger of 7 g/dL would be safe in critically pa-
tients with CVD diseases. More recently, Rao et al65 ex-
amined detailed prospectively collected data for 24,112
patients who were enrolled in 3 international randomized
trials in patients with acute coronary syndromes. Of these
patients 2,401 (10%) received at least 1 transfusion during
hospitalization. Using complex statistical approaches,
which included adjustments for comorbidities and time
from admission, authors found an increased risk for 30-day
mortality among patients who received a transfusion. When
the authors explored the importance of the lowest
hemoglobin value in the patients, there was no demonstra-
ble benefit from transfusion on mortality probability in their
statistical model at hematocrit values between 20% to 25%,
while at values above 30% transfusion was associated with
a higher probability for death. These data are difficult to
interpret and illustrate the limitations of cohort studies for
addressing questions concerning anemia, blood transfu-
sions, and outcomes in clinical conditions in which many
factors influence mortality.
There is an urgent need for prospective randomized tri-
als of transfusion strategy for patients with ischemic heart
disease, particularly as up to 28% of general intensive care
populations may have cardiac disease at admission.31
The question of when to transfuse an individual patient
with a coexisting cardiac disease thus remains unanswered
except for the notion that at hemoglobin levels of less than
6.0 g/dL blood transfusions may be indicated in most pa-
tients, in particular in patients with coexisting cardiac dis-
eases.66,67 Because it remains impossible to determine the
magic hemoglobin number at which a transfusion would
be generally indicated, guidelines published in 200662 by
the American Society of Anesthesiologists should be fol-
lowed, stating that “(the decision for) red blood cell trans-
fusions should be based on the patient’s risk of developing
complications of inadequate oxygenation” even for patients
with coexisting cardiovascular disease. The question which
then follows is “what are the signs of a beginning inad-
equate oxygenation in patients with coexisting cardiac dis-
eases?”
Inadequate oxygenation may become manifest locally
in the form of myocardial ischemia or globally in the form
of a general hemodynamic instability with a tendency to
hypotension and tachycardia despite normovolemia. Myo-
cardial ischemia may be detected by continuous 5-lead
electrocardiogram monitoring, ideally with automatic ST-
segment analysis68,69 and by (transesophageal)
echocardiography.70 Therefore, new ST-segment depressions
greater than 0.1 mV or new ST-segment elevations greater
than 0.2 mV during more than 1 minute are generally re-
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garded as markers of myocardial ischemia. During progres-
sive hemodilution, one mostly observes ST-segment depres-
sion,69 suggesting subendocardial ischemia. Such anemia-
related ischemia is reversible by decreasing the heart rate,
if elevated, and by minimal transfusion to increase the
hemoglobin by 1 to 2 g/dL.71 Also, new wall motion ab-
normalities clinically detected by trans-esophageal
echocardiography (and experimentally by sonomicrometry)
are suggestive of myocardial ischemia and can be treated
by an increase in the hemoglobin of only 1 to 2 g/dL.71
Early signs of inadequate circulation generally comprise
hemodynamic instability characterized by a relative tachy-
cardia and hypotension,6 an oxygen extraction rate of
greater than 50%,66,67 a low mixed-venous oxygen partial
pressure (PvO2), or a decrease in oxygen consumption.66,67
In a position report from the College of American Patholo-
gists, an oxygen extraction rate of greater than 50%, a PvO2
less than 25 mm Hg (less than 3.3 kPa), and a reduction in
oxygen consumption to less than 50% of baseline are de-
scribed as threshold values above which a blood transfu-
sion would be indicated.66 An oxygen extraction of greater
than 50% has been found to indicate exhaustion of com-
pensatory mechanism in several studies72,73 and thus repre-
sents a clear indication for transfusion. In contrast, a thresh-
old of 25 mm Hg for PvO2 appears too low, because in the
studies by Moss et al, the PvO2 decreased below the thresh-
old of 25 mm Hg only after circulatory collapse.72 A de-
crease in oxygen consumption greater than 50% at
normovolemia is certainly an indication for transfusion;
however, such a large reduction is usually observed only
after hemodynamic collapse.73 Indeed, oxygen consumption
decreases very late (i.e., at very low hemoglobin levels dur-
ing progressive normovolemic hemodilution ), when oxy-
gen extraction has already increased and PvO2 decreased.73
In some recent experimental studies, acute normovolemic
hemodilution was well tolerated, which corroborates tol-
erance to anemia.74–76 Fantoni DT et al74 showed in a study
with 18 dogs that the hemodynamic response to acute
normovolemic hemodilution was characterized by improve-
ment of the cardiac index, independent of the evaluated
anesthetic agent. Otsuki DA et al75 published an experimen-
tal study with pigs submitted to normovolemic
hemodilution. In this model, the acute normovolemic
hemodilution promoted a decrease in SVO2 and an increase
in cardiac output values. Similar results were demonstrated
by the same group76 in a study that compared tolerance to
oxygen privation during acute normovolemic hemodilution
with different fluids. Perin D et al, in a recent paper, con-
firmed the findings that global and regional stability were
maintained after moderate and severe hemodilution.77 How-
ever, this work showed that severe hemodilution was re-
lated to increased intestinal-arterial PCO2, suggesting that
monitoring gastric mucosal CO2 may be useful during ma-
jor surgery or following trauma.
In patients with coexisting cardiac diseases, the princi-
ples of allogeneic blood transfusion are not basically dif-
ferent than those which apply to healthy patients and are
also largely based on early signs of impaired oxygenation
to specific organs or to the entire organism. In this scenario,
impaired oxygenation may be reached at higher
hemoglobin values than in healthy patients; in addition,
many local logistic factors must be considered when es-
tablishing transfusion guidelines. Clinicians should regu-
larly reassess the likely myocardial oxygen supply/demand
balance of their patients and modify their transfusion de-
cisions based on this information. Considering the response
to anemia on an individual, case by case basis, is more ra-
tional than establishing the same trigger for different pa-
tients with distinct comorbidities.
TRANSFUSION IN SEPTIC PATIENTS
Over the last two decades, there has been much inter-
est in the concept of maximizing oxygen delivery and oxy-
gen consumption in critically ill patients. This approach
was initially suggested as a result of studies by Shoemaker
et al, which suggested that supranormal levels of oxygen
delivery and oxygen usage in critically ill surgical patients
were associated with improved clinical outcomes.38–80 How-
ever, subsequent prospective randomized trials81,82 and an
additional meta-analysis83 have failed to confirm the ben-
efit of achieving supranormal values of oxygen delivery and
oxygen use, raising the possibility that this strategy may
result in worse clinical outcomes and increased mortality.
In patients with sepsis, RBC transfusion has been com-
monly used over the last two decades as a means to aug-
ment systemic oxygen delivery. However, clinical studies
have not consistently demonstrated that this therapeutic
maneuver is accompanied by an increase in oxygen use at
either the whole-body level or at the level of the individual
organs. Although several clinical studies have evaluated
hemodynamic and oxygen transport parameters before and
after RBC transfusion in critically ill patients, few studies
have demonstrated a significant improvement in these vari-
ables after RBC transfusion.
An early study by Shah et al in 198284 evaluated the
impact of RBC transfusion on hemodynamics and oxygen
transport in 8 critically ill trauma patients. Following trans-
fusion of 1 unit of packed RBC (mean hemoglobin increase
from 9.2 g/dL ± 0.3 g/dL to 10.1 g/dL ± 0.3 g/dL), there
were no changes in oxygen delivery, oxygen consumption,
or mixed venous oxygen content. Both cardiac index and
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P50 significantly decreased following transfusion of 2 units
of RBCs. Administration of RBCs thus failed to increase
oxygen consumption in these trauma patients, in spite of
an increase in oxygen content.
Similarly, Kahn et al in 198685 showed that in critically
ill patients, hemodynamic variables were not altered sig-
nificantly by RBC transfusion; however, 2,3 DPG concen-
trations decreased significantly. More recently, the role of
blood transfusion as a means toward improving oxygen
transport was evaluated in 19 critically ill patients with sep-
sis syndrome.86 Oxygen uptake failed to increase in septic
patients with transfusion, despite a significant increase in
hemoglobin.
Treatment recommendations for pediatric patients pre-
senting with septic shock have advocated increasing oxy-
gen consumption (VO2). Mink et al87 prospectively exam-
ined the effect on VO2 of improving oxygen delivery (DO2)
by increasing oxygen content with RBC transfusion in 8
hemodynamically stable septic shock patients. Transfusion
significantly increased hemoglobin and hematocrit from
10.2 g/dL ± 0.8 g/dL and 30% ± 2% to 13.2 g/dL ± 1.4 g/
dL and 39% ± 4%, respectively (mean ± SD). Although
DO2 significantly increased after RBC transfusion, VO2 did
not change significantly. Therefore, in pediatric septic
shock patients, increasing oxygen content by blood trans-
fusion did not increase VO2.
Similar findings have been demonstrated in adult pa-
tients with shock. Dietrich et al88 examined the cardiovas-
cular and metabolic response to RBCs in patients with cir-
culatory shock after volume resuscitation. Although DO2
was increased by 28% with RBCs, neither pulmonary ar-
tery wedge pressure, cardiac index, VO2, nor lactate was
changed by augmentation of red cell mass. An increase was
observed in myocardial work indices and in the MAP × HR
product. No changes were identified when subgroups were
analyzed based on diagnosis, pretransfusion Hgb, lactate,
or VO2 levels.
Lorente et al89 performed a prospective, randomized,
interventional cross-over study to investigate whether in-
creasing DO2 by increasing hematocrit results in increases
in VO2 in septic patients. A sample of 16 consecutive pa-
tients admitted to the ICU who were diagnosed as having
severe sepsis by defined criteria and who had a hemoglobin
concentration of less than 10 g/dL were enrolled. Patients
received, in random order, an infusion of dobutamine (10
ìg/kg per minute) and a blood transfusion (800 mL of
packed RBCs in 90 minutes). Changes in DO2 and VO2 in-
duced by each intervention were measured. Dobutamine
significantly increased DO2 (48.5% ± 6.9%; P = .0001) and
VO2 (21.7% ± 3.3%; P =.0001). Blood transfusion in-
creased DO2 (21.4% ± 4.3%; P = .005), but VO2 did not
change significantly (2.2% ± 4.1%). Correlation coeffi-
cients for the percent changes of DO2 and VO2 (r2 = 0.67,
P = .001 for dobutamine; and r2 = 21, P = .07 for blood
transfusion) were significantly different for each treatment
(P = .0001). The authors concluded that in patients with
an abnormal DO2-dependent VO2, as shown by increases
in VO2 brought about by an infusion of dobutamine, blood
transfusion did not increase VO2 significantly, despite sig-
nificant changes in DO2.
A recent study by Fernandes et al90 evaluated
hemodynamics and oxygen usage induced by hemoglobin
infusion in critically ill septic patients. Hemodynamic data,
gastric tonometry, and calorimetry were obtained before
and immediately after RBC transfusion or 5% albumin in-
fusion. This study documented that an increase in
hemoglobin did not improve global or regional oxygen use
in anemic septic patients. Furthermore, RBC transfusion
may hamper right ventricular ejection by increasing the
pulmonary vascular resistance index.
Recently, a study published by Rivers et al50 documented
that the use of early goal-directed care based on
hemodynamic variables and a mixed central venous satu-
ration decreased mortality from 46.5% in the control group
to 30.5% in the goal-directed therapy group (P = .009) in
patients identified in the first 6 hours of septic shock. As
one of the many interventions in patients with early septic
shock, hematocrit concentrations were increased beyond
30% if the central venous saturations fell below 70% after
fluid reposition. As a consequence of goal-directed therapy,
64% of patients when compared with 18.5% of the con-
trol group received RBC transfusions in the first 6 hours
of care (P < .0001). However, given the complexity of care
provided in the early goal-directed therapy trial, it is un-
clear how much benefit was derived from a higher trans-
fusion trigger when compared with other interventions
within the algorithm, which included fluid challenges,
blood transfusion, and dobutamine infusion.50
In patients with sepsis and other shock states, RBC
transfusion is commonly used to increase oxygen transport.
The expected benefit from RBC transfusion is to immedi-
ately improve oxygen delivery and thus prevent cellular in-
jury. The question regarding whether RBC transfusion im-
proves regional microcirculation is important, since the goal
of resuscitation is to improve organ perfusion and to pre-
vent organ failure. Other studies have failed to demonstrate
benefits of transfusion in septic patients.91–95
Considering the evidence from above cited studies, sep-
tic patients do not benefit from a higher hemoglobin level.
The benefits of transfusion are questionable, and the risks
are known in this population. Consequently, the Surviving
Sepsis Campaign recommends that septic patients should
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be managed with a conservative strategy, tolerating
hemoglobin levels around 7 g/dL.33
THE STORED BLOOD CELL
The delivery of oxygen to tissues is the primary func-
tion of the erythrocyte. The aim of transfusion of banked
red cells must be to improve tissue oxygen delivery (not
oxygen carrying capacity). Other rationales for transfusion
(e.g., volume expansion, support of blood pressure, and
wound healing) have been promoted; however, all contem-
porary guidelines specifically are couched in terms of oxy-
gen availability and delivery.
Inside the red cell a stable concentration (20-25 ìmol)
of 2,3 diphosphoglycerate (2,3 DPG) is found which regu-
lates the oxyhemoglobin dissociation curve and right-shifts
the curve. With normal 2,3 DPG, the P50 or partial pres-
sure of oxygen at which hemoglobin is 50% saturated is
approximately 26 mm Hg.96–98 Other metabolic byproducts
have dramatic effects on the oxyhemoglobin dissociation
curve as well. Hydrogen ion drives the curve to the right,
increasing the release of oxygen as does carbon dioxide.
Acidosis, therefore, increases the movement of oxygen out
of hemoglobin. Under normal conditions, because of the
oxyhemoglobin dissociation curve, it is possible for eryth-
rocytes to unload a maximum 26% of their total oxygen
load. For erythrocytes stored as banked blood, the maxi-
mum release of oxygen is considerably less (probably about
6% or less). The P50 of stored blood depends on how long
it has been stored and the intracellular 2,3 DPG. The P50
of stored blood at 28 days is about 6 to 11 mm Hg.97,99
Of interest, the P50 of myoglobin, a target for oxygen
delivery by the red cell, is 5 mm Hg.97,99
Stored red cells not only exhibit a decrease in intracel-
lular 2,3 DPG that leads to decreased oxygen release, but
as they age in storage they undergo a number of other cel-
lular changes. Biochemical, hormonal, inflammatory, and
cellular structural changes all occur. Red cells change from
their normal biconcave discoid shape to a globular swol-
len (spherocyte), or to a spiculated (shistocyte) shape. Ini-
tially, by day 5 to 10, red cells get spicules on the surface
of their membranes.100 These spicules fall off, and the cells
become rounded (spherocytes) but also swell and lose their
flexibility. They lose approximately 15% to 20% of their
cell membrane phospholipids by day 15 to 28.100 As the red
cells survive in their anoxic environment, they lose their
Na-K ATPase function, and become edematous. With cell
swelling and loss of lipid membrane material, red cells be-
come very stiff and quite friable. They are prone to early
destruction, and, if cytokines are present, they are rapidly
sequestered and have a shortened circulating half-life.
The combined effects of low P50, dysfunctional cell flex-
ibility, bizarre cellular shapes, and erythrocyte clumping
means that banked blood is very poor at perfusing the cap-
illary microcirculation. Studies examining blood flow to the
microcirculation have shown that when stored red cells are
used, there is a dramatic reduction of flow. In rat models
of hemorrhagic shock, both the mesenteric blood flow and
the hippocampal blood flow are only reestablished with
fresh blood.101,102 Stored rat blood to resuscitate hemorrhagic
shock only leads to a 10% restoration of flow.
Stored erythrocytes take up oxygen, but are not efficient
in patients after coronary artery bypass surgery grafting sur-
gery: no increase in oxygen delivery to the microcircula-
tion results from transfusion of 1 or 2 units of blood.101 Fur-
thermore, in some critically ill patients, it has been shown
that transfusing banked blood actually decreases gut oxy-
gen delivery, making the tissues more acidotic.102,103
Available evidence shows that RBC transfusion is not
associated with improvements in clinical outcome in the
critically ill and may result in worse outcomes in some pa-
tients. Lack of efficacy of RBC transfusion is likely to be
related to storage time, increased endothelial adherence of
stored RBCs, nitric oxide binding by free hemoglobin in
stored blood, donor leukocytes, host inflammatory re-
sponse, and reduced red cell deformability.
TRANSFUSION-ASSOCIATED RISKS
Transfusion-related risks can be divided into transfu-
sion-transmissible infections, immunological risks, and
mistransfusion.
Infectious risks
Red blood cell transfusion in developed countries has
probably never been safer than today with respect to trans-
fusion-transmissible viruses such as HIV, hepatitis B virus,
and hepatitis C virus.105 In these countries, the estimated
risks of infection have dramatically decreased over recent
years as increased test sensitivity has reduced the infectious
window periods. In contrast, viral infections are still a ma-
jor problem in developing countries.105 A high
seroprevalence of these diseases in the general population
of these countries, poor blood donation systems, and poor
sensitivity of pathogen testing are important factors. Dur-
ing the last decades of the twentieth century, substantial
scientific and lay press attention was focused on infectious
risks including transfusion-associated hepatitis B and C,
HIV, West Nile virus, and Variant Creutzfeldt-Jakob dis-
ease. With the addition of heightened donor screening and
antibody, antigen, and/or nucleic acid testing, many of the
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concerns regarding transfusion-transmission of infectious
diseases have been well addressed and largely mitigated or
eliminated. Compared with viral infections, at he time of
writing there is much more concern about transfusion-trans-
mitted bacterial infections and post-transfusion sepsis.
A significant association between the number of RBC
transfusions and subsequent infection has been reported in
patients following trauma, burns, and a variety of surgical
procedures, both elective and emergency.105,106 A recent
meta-analysis106 with 13,152 patients has demonstrated the
relationship of allogeneic blood transfusion to postopera-
tive bacterial infection using 20 peer-reviewed studies pub-
lished from 1986 to 2000. The common odds ratio for the
risk of infection associated with RBC transfusion in this
meta-analysis was 3.45 (range, 1.43 to 15.15), with 17 of
the 20 studies demonstrating a value of P d” .05. These
results provide overwhelming evidence that RBC transfu-
sion is associated with a significantly increased risk of post-
operative bacterial infection in the surgical patient. Simi-
larly, in the critically ill, Taylor et al have demonstrated
an association between RBC transfusion and nosocomial
infection and mortality.107
These data in turn have led to the hypothesis that trans-
fusing patients with leukoreduced blood should result in
reduced morbidity and mortality compared with patients
receiving nonleukoreduced transfusions. Meta-analyses of
the literature have failed to identify a statistically signifi-
cant effect of leukoreduction108,109 on outcomes associated
with blood transfusion. A recent study evaluating clinical
outcomes following the institution of a universal pre-stor-
age leukoreduction program in Canada noted a reduction
in hospital mortality following introduction of this pro-
gram.110 On the other hand, a randomized prospective study
comparing outcomes in patients (n = 2,780) receiving ei-
ther leukoreduced or nonleukoreduced RBCs failed to dem-
onstrate any beneficial effect of leukoreduction on clini-
cal outcome, including in-hospital mortality, ICU length of
stay or readmission rates, or antibiotic usage.111
Recently, the first possible cases of transfusion-trans-
mitted variant Creutzfeld-Jakob disease have been re-
ported.112
Immunological risks
Red cell transfusion with allogeneic blood is a pro-
foundly inflammatory mixture.113–116 It contains high lev-
els of a many different cytokines, bradykinin, serotonin, and
living white cells. A large body of literature exists show-
ing a relationship between the infusion of red cells in trans-
fusion and early postoperative increased rates of infec-
tion.117–120 Such infections manifest as wound infections,
higher pneumonia rates, dehiscence, and, in orthopedic
joint replacements, osteomyelitis.
In years past when early renal transplantation was be-
ing developed, it was the practice of those performing re-
nal transplants to give every patient a transfusion because
they were aware of the immunosuppressive effects of
blood.118 Indeed, patients who received transfusion at the
time of surgery had fewer acute and chronic rejection epi-
sodes. It has been estimated that a single unit of packed
red blood cells that is not leukoreduced provides the same
immunosuppression as a dose of cyclosporine. Conversely,
transfusion at, or immediately after, colon resection for co-
lon cancer has been widely investigated, and shows a rela-
tionship between transfusion and early metastasis and also
early death. The same has not been shown in other can-
cers such as prostate cancer, but probably the same mecha-
nisms of immunosuppression that led to more perioperative
infection may also lead to the potential implantation or
growth of metastatic cell implants.
Engoren et al121 quoting from their database with regard
to both long- and short-term death rates in relationship to
transfusion report a relationship of transfusion use to death
rate in more than 1900 coronary artery bypass patients fol-
lowed up for 60 months. Patients who had transfusion at
or near the time of their operation had at least twice the
death rate as those not having it, and the Kaplan-Meier sur-
vival curves continued to diverge all the way out to 5 years
after surgery.
It has been documented that blood transfusion is a risk
factor for the development of multiple organ failure and
worse outcome in trauma and surgical patients. In a pro-
spective study, Zallen et al further documented an inde-
pendent risk factor for post-injury multiple organ failure
associated to the age of RBCs transfused during the first 6
hours of treatment.114 Multivariate analysis identified mean
age of blood, number of units older than 14 days, and
number of units older than 21 days as independent risk fac-
tors for multiple organ failure. One hypothesis is that stored
RBCs (older than 14 days) can prime polymorpho-
neutrophils (PMNs) and thereby provoke multiple organ
failure. A recent in vitro study documented that plasma
from 42-day-old RBCs stimulated significant release of
interleukin (IL)-8 and secretory phospholipase A2 by PMNs
as compared with controls and fresh plasma (day 0) .115
Emerging data therefore indicate that transfused blood is
an inflammatory agent capable of producing PMN prim-
ing that may promote organ dysfunction.
Transfusion-related acute lung injury (TRALI) is now
considered to be the second leading cause of mortality from
transfusion and has emerged as the leading cause of trans-
fusion-related deaths reported to the US Food and Drug
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Administration, though this is most likely because of in-
creased recognition and may in fact represent an
overdiagnosis.85 It has been associated with various blood
products including whole blood, packed red blood cells,
apheresis, or whole blood-derived platelets, fresh frozen
plasma, granulocytes, intravenous immunoglobulin, and
cryoprecipitate.85
The first cases of what was likely to have been TRALI
appeared in the literature in the early 1950s, and approxi-
mately 20 years later an association with leukoagglutinins
was suspected as the cause.122 It was still another 15 years
before the first case series was published122 with diagnoses
based on clinical symptoms. In fact, it was not until 2003
that clinical criteria were proposed in which an agreed-upon
diagnosis of TRALI could be proffered.
Clinically, patients who have TRALI present with a syn-
drome that can be characterized as having noncardiogenic
pulmonary edema with dyspnea, acute hypoxemia, hypo-
tension, and occasionally fever.123 Bilateral infiltrates are
usually described on chest radiograph; however, because
of interpretation, type of study, and patient positioning, this
can be variable. Signs of congestive heart failure (increased
jugular venous pressure and/or a third heart sound) are usu-
ally absent. The pulmonary capillary wedge pressure is
typically normal. Symptoms usually appear 1 to 6 hours
after transfusion and resolve in less than 48 hours.
In May 2003, the National Heart, Lung, and Blood In-
stitute (NHLBI) convened a working group that sought to
develop a common definition of TRALI.122,124 They started
with the American–European Consensus Committee’s defi-
nition (acute hypoxemia with PaO2/FIO2 ratio d” 300 mm
Hg for acute lung injury (ALI) [d” 200 mm Hg for acute
respiratory distress syndrome (ARDS)] or oxygen satura-
tion of d” 90%, and the appearance of bilateral infiltrates
in the absence of left atrial hypertension). Then, in their
definition, cases of new ALI occurring within 6 hours of
transfusion in patients who have no other risk factors for
lung injury are classified as TRALI. When additional risk
factors for ALI other than transfusion are present, the di-
agnosis of TRALI is made based on temporal association
with transfusion and clinical course. TRALI is defined as:
(1) a new occurrence of acute onset ALI (with hypoxemia
and bilateral infiltrates on chest radiograph but no evidence
of left atrial hypertension), (2) not preexisting, but (3)
emerging during or within 6 hours of the end of the trans-
fusion, and (4) having no temporal relationship with an al-
ternative TRALI risk factor.122,124
Popovsky and Moore125 reported 36 cases of TRALI in
1985, with an incidence of 0.02% per unit and 0.16% per
patient for all blood products. Other more recent studies
have reported widely varying incidence rates ranging from
1:432 whole blood units to 1:557 000 per RBC unit. The
real incidence of the transfusion-related reactions under-
pinning TRALI remains unknown. However, increasing
awareness among clinicians of the pathologic entity, com-
bined with an evolution of its definition toward including
less severe cases, is likely to increase the reported inci-
dence. In fact, the number of TRALI-related fatalities re-
ported to the US Food and Drug Administration from 2001
to 2003 has steadily risen from 1995;126 TRALI is now the
most frequently reported cause of transfusion-related
death.127
The pathophysiological mechanisms of TRALI are in-
completely, if at all, understood and have been described
as antibody-mediated and non-antibody-mediated, respec-
tively.126,127
Broad prevention strategies have been advocated, in-
cluding deferral of donors with high likelihood of being
previously alloimmunized, universal leukoreduction, greater
reliance on apheresis platelets, the strict use of “young”
units, and the use of washed products.127 Each of these strat-
egies has disadvantages, including added cost, the poten-
tial to worsen already significant blood supply shortages,
and uncertain levels of preventive efficacy. However, some
feel that the risk of TRALI warrants these measures.
With the success of reducing the risk of transfusion-
transmitted infectious diseases, serious noninfectious haz-
ards of transfusion have come to the forefront with respect
to transfusion safety. Improved understanding of its patho-
physiology is needed to improve clinical strategies to deal
with the risk. Such understanding, in turn, will depend on
the continued progress in development of good model sys-
tems, in vitro and in vivo, for experimental studies. Finally,
as the pathologic mechanisms are elucidated, a universal
definition and strategies for the prevention and/or mitiga-
tion may become more feasible.
Mistransfusion
Mistransfusion is estimated to occur in 1:14 000 to 1:18
000 transfusions and thus is one of the most frequent trans-
fusion hazards, associated with significant morbidity and
mortality.122
CONCLUSIONS AND PERSPECTIVES
Widespread concern about complications associated
with RBC transfusion has led to the scrutiny of traditional
transfusion practices. Recently, attempts have been made
to evaluate the efficacy of RBC transfusion and thereby to
more clearly define the indications for RBC transfusions
in patients, particularly those who are critically ill. Al-
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though available studies about transfusion are very com-
prehensive, most are only observational studies and there-
fore do not strongly assist clinicians in deciding when to
transfuse. Nevertheless, some important lessons can be
learned from these studies. The first is that anemia is ex-
tremely common in critically ill patients and therefore is
almost to be expected.
The second lesson is that very often the only reason for
giving a blood transfusion to patients is that they have a
low hemoglobin value. One must assume that these trans-
fusions are given with the hope of improving oxygen de-
livery in some way. However, usually it is not possible to
determine oxygen delivery and tissue extraction adequately.
The third lesson is that allogeneic blood transfusion may
be injurious to patients. The associations found in these
studies between more units transfused and evidence of
worse outcome is not unexpected. Over the years, an in-
creasing volume of data seem to indicate that there are sig-
nificant harmful effects of blood transfusions.
As mentioned earlier, a hemoglobin-based transfusion
trigger does not take into account the individual patient’s
ability to tolerate and compensate for anemia. Therefore,
appropriate transfusion guidelines should be based prima-
rily on physiological transfusion triggers, whereas
hemoglobin-based transfusion triggers should serve as an
aid in cases of insufficient or unreliable information on the
patient’s global or regional tissue oxygenation. We must
move away from “triggers” to individualize transfusion
practices. Global signs of inadequate oxygenation are
hemodynamic instability, oxygen extraction (O2ER) > 50%,
a mixed venous oxygen saturation (SVO2) < 50%, a low
mixed venous oxygen partial pressure (PVO2), decrease in
VO2 and evidence of myocardial ischemia.
The adoption of available blood conservation tech-
niques, either alone or in combination, could result in re-
duction of unnecessary transfusions and in lower risk. Al-
ternative methods of conservation include meticulous
hemostasis in surgical patients,129 erythropoietin adminis-
tration,130,131 use of factor VIIa132 or desmopressin,133 use of
hemodilution,134 reduction of phlebotomy losses, and reduc-
tion of trigger.
From the pooled data regarding the efficacy of RBC
transfusions in the critically ill, conservative RBC transfu-
sion strategies in critical care have reduced the risk of trans-
fusion-related adverse effects. The TRICC trial has estab-
lished the safety of a restrictive strategy, suggesting that
physicians could minimize exposure to allogeneic RBCs
by lowering their transfusion threshold. Additional studies
will be necessary to identify patients who will improve
from RBC transfusion and to determine the effects of RBC
storage time and the presence of allogeneic leukocytes in
allogeneic RBCs.
RESUMO
Hajjar l, Auler Junior JOC, Santos L, Galas F. Transfusão
de sangue em pacientes críticos: estado da arte. CLINICS.
2007;62(4):507-24.
A transfusão no paciente crítico vem sendo alvo de dis-
cussões recentes considerando seus reais benefícios na re-
dução de morbi-mortalidade e os riscos associados ao pro-
cedimento. Nos últimos anos, alguns estudos controlados
e randomizados tiveram como objetivo comparar desfechos
clínicos entre pacientes que receberam transfusão de ma-
neira mais liberal (hemoglobina alvo em torno de 9 g/dL)
e transfusão de maneira mais restritiva (hemoglobina em
torno de 7 g/dL). Os resultados demonstram a não superi-
oridade da estratégia liberal comparada com a restritiva.
Além disso, em alguns subgrupos de pacientes menos gra-
ves ou de menor idade, a transfusão foi associada com pi-
ores desfechos clínicos. Os riscos da transfusão de sangue
no paciente crítico incluem desde incidência maior de in-
fecções bacterianas, infecções virais, imunodepressão, re-
ações hemolíticas e lesões teciduais inflamatórias, dentre
outros. Algumas estratégias vêm sendo analisadas com o
objetivo de redução dos riscos da transfusão e incluem
leucorredução, implementação de medidas visando
minimizar o tempo de estocagem entre outras. Consensos
e recomendações recentes sugerem estratégia restritiva
transfusional, estimulando uma prática que visa minimizar
as perdas sanguíneas, reduzir o limiar crítico da
hemoglobina, detectar anemia e tratá-la, e utilizar estraté-
gias à transfusão, como o uso de antifibrinolíticos e da
eritropoietina. O objetivo dessa revisão é avaliar à luz dos
conhecimentos atuais as evidências em torno da transfu-
são no paciente crítico em diferentes situações, propondo
a racionalização das indicações de transfusão, consideran-
do metas a serem atingidas, com o objetivo de minimizar
a morbi-mortalidade do paciente crítico.
UNITERMOS: Anemia, Transfusão, Pacientes Críticos,
Entrega do oxigênio, Resultados.
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